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Abstract We report the sequence of the cDNA encoding human 
L-3-phosphoserine phosphatase. The encoded polypeptide con-
tains 225 residues and shows 30% sequence identity with the 
Escherichia coli enzyme. The human protein was expressed in a 
bacterial expression system and purified. Similar to known L - 3 -
phosphoserine phosphatases, it catalyzed the Mg2+-dependent 
hydrolysis of L-phosphoserine and an exchange reaction between 
L-serine and L-phosphoserine. In addition we found that the 
enzyme was phosphorylated upon incubation with L-
|32P|phosphoserine, which indicates that the reaction mechanism 
proceeds via the formation of a phosphoryl-enzyme intermediate. 
The sensitivity of the phosphoryl-enzyme to alkali and to 
hydroxylamine suggests that an aspartyl- or a glutamyl-
phosphate was formed. The nucleotide sequence of the cDNA 
described in this article has been deposited in the EMBL data 
base under accession number Y10275. 
© 1997 Federation of European Biochemical Societies. 
1. Introduction 
L-3-Phosphoserine phosphatase is the enzyme responsible 
for the third and last step in L-serine formation. This enzyme 
not only catalyzes the Mg 2 + -dependent hydrolysis of L-phos-
phoserine but also an exchange reaction between L-serine and 
L-phosphoserine [1,2], suggesting that its reaction mechanism 
proceeds through the formation of a phosphoryl-enzyme in-
termediate; the latter has, however, never been directly dem-
onstrated. As L-3-phosphoserine phosphatase has been re-
ported to be deficient in one case of L-serine deficiency [3], 
it was of interest to determine the sequence of the human 
enzyme. Da tabanks contain D N A sequences of several bacte-
ria and of two eukaryotes (Saccharomyces cerevisiae and 
Schistosoma mansoni) that are homologous to SerB, the 
gene encoding Escherichia coli L-3-phosphoserine phosphatase 
[4]. 
In this paper we report the sequence of the human enzyme. 
We have also expressed an active protein and show that it 
forms a phosphoenzyme when incubated with its substrate. 
2. Material and methods 
2.1. Materials 
L-[32P]Phosphoserine was synthesized by incubating 1 mM L-serine 
with 10 μΜ 32P-labeled inorganic pyrophosphate (0.10 mCi), 2 mM 
magnesium acetate, 1 mM dithiothreitol, 25 mM Tris-HCl (pH 7.1), 
and 0.03 U pyrophosphate: L-serine phosphotransferase [5] for 40 min 
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at 30°C in a final volume of 3 ml; it was purified as in [6]. Radioactive 
compounds and Thermosequenase were from Amersham and Pwo 
polymerase from Boehringer. Chemicals were from Sigma or Merck. 
Clones R14208, N23530, N42133, W05752, H38879 and T82144 from 
the IMAGE consortium [7], were kindly provided by the UK HGMP 
Resource Centre. 
2.2. Amplification of cDNA 
DNA obtained from human cDNA libraries (from renal cell carci-
noma line LE9211-RCC [8], from the urinary bladder transitional-cell 
carcinoma LB831-BLC, or from EBV-transformed lymphoblastoid 
cell line LG2-EBV [9]) was amplified with Pwo polymerase (a polym-
erase with proofreading activity) using two primers chosen as de-
scribed in Section 3. The first (GTGCATATGGTCTCCCACTCA-
GAGCTG) had a start codon (underlined) inserted in a Ndel site 
and the second (ACGGATCCTCATCTGAAGTTGTTTGGAGC) 
corresponded to nucleotides 882-902 of the sequence that we report 
in the EMBL databank, flanked by a BamHl site. The PCR-amplified 
product obtained with the human kidney library was purified by 
agarose gel electrophoresis, inserted in the EcoRV site of pBluescript 
and sequenced. 
2.3. Expression and purification of recombinant human 
L-3-phosphoserine phosphatase 
The insert of the resulting plasmid was excised with Ndel and 
Bamlil restriction enzymes and ligated in the expression vector 
pET3a [10]. BL21(DE3)pLysS cells were transformed with this plas-
mid and were aerobically grown in M9 medium at 37°C until Af,oo 
reached 0.5-0.6. The culture was then maintained on ice for 15 min, 
after which time isopropylthiogalactoside was added to a final con-
centration of 0.4 mM. After 20 h of incubation at 37°C, bacterial 
extracts were prepared as described [11], the lysis buffer being supple-
mented with 5 μg/ml of antipain and 5 μg/ml of leupeptin. The extract 
was centrifuged for 40 min (20000Xg at 4°C). The resulting super-
natant (25 ml) was diluted 3-fold with buffer A (10 mM Tris-HCl (pH 
8.5), 1 mM dithiothreitol, 1 μg/ml leupeptin, 1 μg/ml antipain) and 
applied onto a DEAE-Sepharose column (1.6X10 cm). The column 
was washed with 100 ml of buffer A and protein was eluted with a 
NaCl gradient (0^4-00 mM in 250 ml of buffer A). L-3-Phosphoserine 
phosphatase came out at a Na' concentration of 250 mM. The active 
fractions were pooled and concentrated 4-fold by ultrafiltration in an 
Amicon cell (YM-10 membrane). Two milliliters of this preparation 
were further purified by gel filtration on Sephacryl S-200 (1.6X50 cm) 
in buffer B (20 mM Hepes (pH 7.5), 1 mM dithiothreitol, 100 mM 
KC1, 0.5 μg/ml leupeptin and 0.5 μg/ml antipain) at a flow rate of 0.25 
ml/min. 
2.4. Purification and sequencing of rat liver 
L-3-phosphoserine phosphatase 
L-3-Phosphoserine phosphatase was purified from rat liver by a 
previously described procedure [12], followed by a gel filtration on 
Sephacryl S-200 equilibrated with buffer B. The active fractions 
were submitted to SDS-PAGE. Staining with Coomassie Blue re-
vealed the presence of about 10 bands with Mr 20000-70000. The 
gel was sliced, and the polypeptides were extracted and subjected to a 
renaturation procedure [13]. Phosphoserine phosphatase activity was 
observed only in the fraction corresponding to a 25 000 MT polypep-
tide. Tryptic peptides were obtained from this protein and sequenced 
as described [14]. 
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Fig. 1. Alignment of 1-3-phosphoserine phosphatase sequences from various species (ratu: Rattus norvegicus; schi: Schistosoma mansoni; homo: 
Homo sapiens; esch: Escherichia coli; haem: Haemophilus influenzae; meth: Methanococcus jannaschii; sacc: Saccharomyces cerevisiae). The 
tryptic peptides are shown for the rat enzyme. Similar and conserved residues are shown in boxes. 
2.5. Enzyme assays 
In the course of its purification, L-3-phosphoserine phosphatase was 
assayed at 30°C by the release of Pi from unlabelled L-phosphoserine 
in an assay mixture (250 μΐ) containing 25 mM Mes (pH 6.5), 5 mM 
MgCl2, 1 mM dithiothreitol, 5 mM L-phosphoserine, 0.1 mg/ml bo-
vine serum albumin and 1-10 mU L-3-phosphoserine phosphatase. 
Reactions were stopped by the addition of 250 μΐ of 10% trichloro-
acetic acid (TCA) and Pi was measured [15]. One unit of enzyme is the 
amount that catalyzes the conversion of 1 umol of substrate per 
minute under these conditions. For kinetic studies, the enzyme was 
assayed by the release of [32P]Pi from L-[32P]phosphoserine [16] in the 
assay mixture described above. The exchange reaction was measured 
by the incorporation of L-[14C]serine into L-phosphoserine in an assay 
mixture containing 25 mM Hepes (pH 7.5), 1 mM dithiothreitol, 
1 mM MgCl2, 1 mM L-phosphoserine, 0.5 mM L-serine and 20000 
cpm L-[14C]serine in a final volume of 100 μΐ. The incubation was 
arrested by spotting 25 μΐ of the reaction mixture on Whatman DE-
81 papers, which were washed in water, dried and counted for radio-
activity in the presence of 5 ml of HiSafe 2 scintillant. 
2.6. Demonstration of the formation of the phosphoenzyme 
Unless otherwise indicated, about 0.15 U of recombinant L-3-phos-
phoserine phosphatase was incubated at 0°C in a mixture containing 
50 mM Hepes (pH 7.5), 1 mM dithiothreitol, 1 μΜ L-phosphoserine, 
60000 cpm of L-[32P]phosphoserine, 5 mM MgCi2, 20 mM L-serine 
and 1 mg/ml bovine serum albumin in a volume of 100 μΐ. The re-
action was stopped at the indicated times by the addition of 250 μΐ of 
5% TCA and filtration on a polyethersulfone membrane (Supor® 200, 
from Gelman). The membrane was washed with 10 ml of TCA 5% 
and counted for radioactivity with 5 ml of HiSafe 2 scintillant. 
2.7. Other methods 
Protein was measured according to Bradford [17] with bovine gam-
ma-globulin as a standard. Sequencing was performed using T7 Ther-
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mo Sequenase (Amersham), fluorescent primers and the LI-COR au-
tomated DNA sequencer 4000L. 
3. Results 
3.1. Identification and sequencing of human cDNAs 
The predicted amino acid sequence of the S. mansoni en-
zyme, most likely the closest to that of the human enzyme, 
was used to perform a Blast search [18]. Several human ESTs 
(expressed-sequence tags) were identified, which corresponded 
to the 5' (IMAGE Consortium [LLNL] cDNA clones 
R14208; N23530; N42133; W05752) or the 3' end (clones 
H38879 and T82144) of the parasite enzyme's open reading 
frame. Oligonucleotide primers derived from these sequences 
were used in PCR reactions to amplify human cDNAs derived 
from bladder or kidney tumor cells, or of lymphocytes. In all 
cases one single fragment of 725 bp was obtained. The frag-
ment obtained by amplification of the kidney cell cDNA was 
cloned in pBluescript and sequenced. Several of the above-
mentioned clones were also sequenced. The composite se-
quence of the reconstituted human cDNA is reported in the 
EMBL databank. Note that clones N42133 and W05752 
lacked nucleotides 281 to 757, and that in clone N23530, there 
was a 122 bp insert homologous to the Alu I family between 
nucleotides 280 and 758. 
The sequence totals 1600 bp; the 5' and 3' non-coding 
regions amount to 187 and 735 bp, respectively. The ATG 
codon opens a reading frame of 675 bp, encoding a protein 
of 225 amino acids. This protein shows 30% and 40% se-
quence identity with the enzymes from E. coli and S. mansoni, 
respectively. It shows also a high degree of identity with sev-
eral peptides derived from L-3-phosphoserine phosphatase pu-
rified from rat liver (Fig. 1). 
3.2. Expression and characterization of a recombinant protein 
To check that the sequence encoded L-3-phosphoserine 
phosphatase, the open reading frame was inserted in pET3a 
[10] and expressed in E. coli. Induction of the cells with iso-
propylthiogalactoside led to the appearance of a 25 000 MT 
polypeptide which after 20 h represented about 5% of the 
soluble proteins. L-3-Phosphoserine phosphatase was purified 
by chromatography on DEAE-Sepharose and Sephacryl S-
200, from which it was eluted with an apparent molecular 
mass of 50000 Mr, indicating a dimeric structure (not shown). 
The purified protein had a specific activity of 6 U/mg protein, 
the yield of the purification being 25%. 
The purified protein was dependent for its activity on the 
presence of Mg2+, which half-maximally stimulated the en-
zyme at 5 mM. It displayed a Km of 20 μΜ for L-phospho-
serine in the presence of 1 mM Mg2+, was non-competitively 
inhibited by L-serine (K¡ =0.5 mM) and catalyzed an exchange 
reaction (incorporation of L-[14C]serine into L-phosphoserine) 
at a rate about 50% that of the hydrolysis (3 μmol/min/mg 
protein). These properties are similar to those of other L-3-
phosphoserine phosphatases [1,2,19]. Other phosphate esters 
(glucose 6-phosphate, fructose 6-phosphate, glycerol 2- or 3-
phosphate and 3-phosphoglycerate, all tested at 5 mM) were 
not significantly hydrolyzed by the purified preparation. 
3.3. Demonstration of the formation of a phosphoenzyme 
Upon incubation of human L-3-phosphoserine phosphatase 
with L-[32P]phosphoserine, a phosphoenzyme was formed. 
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Fig. 2. Time-course of the labelling of the rat liver enzyme with 
L-[32P]phosphoserine. L-3-Phosphoserine phosphatase (0.15 U) was 
incubated at 0°C in the presence of radiolabelled L-phosphoserine 
with (o) or without (·) 10 mM L-serine. 
This could be demonstrated using a method in which protein 
was precipitated in acid and immediately isolated by filtration. 
Other methods in which filters are washed for prolonged time 
(30-60 min) [20,21] yielded insignificant incorporation, pre-
sumably because of the lability of the phosphoenzyme (see 
below). As shown in Fig. 2, the formation of the phosphoen-
zyme was greatly favored by L-serine which acted most likely 
by slowing down the degradation of L-phosphoserine. In the 
presence of 10 mM L-serine, the Km for the formation of this 
phosphoenzyme was 5 μΜ and a maximum of 2.5 nmol of 
phosphate was incorporated per milligram of protein, indicat-
ing a stoichiometry of 0.06 mole per mole of enzyme subunit 
(not shown). SDS-PAGE [22] under denaturing conditions (at 
0°C, to minimize hydrolysis) confirmed that the phosphate 
was only incorporated into the 25000 Μτ polypeptide (not 
shown). The phosphoenzyme was acid labile, being 50% hy-
drolyzed after 50 min of incubation in 5% TCA at 50°C. It 
was extremely labile in alkali, since it was completely lost 
when resuspended in 1 M NaOH at 0°C and reprecipitated 
in TCA. It was also completely hydrolyzed when resuspended 
in 0.2 M NH2OH at pH 5.3 (not shown) and maintained for 
10 min at 20°C. 
4. Discussion 
We report here the identification of clones encoding human 
L-3-phosphoserine phosphatase. This identification rests on 
the similarity of the encoded protein with the E. coli enzyme 
as well as with tryptic peptides derived from the purified rat 
liver enzyme. The identity was confirmed by expression of the 
cDNA and demonstration that the encoded protein behaved 
as a specific L-3-phosphoserine phosphatase with properties 
similar to those of the enzyme present in mammalian tissues. 
The fact that L-3-phosphoserine phosphatase catalyzes an 
exchange reaction between L-serine and L-phosphoserine and 
that it is non-competitively inhibited by L-serine suggested 
that the mechanism of this enzyme involved the formation 
of a phosphoenzyme. This is also consistent with its sensitivity 
to vanadate [23,24]. We show in this work that, indeed, a 
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phosphorylated enzyme is formed upon incubation with the 
substrate. 
Many phosphotransferases proceed through the formation 
of a phosphoenzyme. Four different types of residues have 
been shown to be implicated in covalently binding phosphate 
in these enzymes: serine, as in alkaline phosphatase [25]; his-
tidine, as in acid phosphatase [26], fructose 2,6-bisphosphatase 
[27] and phosphoglycerate mutase [28]; cysteine in tyrosine 
phosphatases [29]; and aspartate in ATPases of the Na+/K+ 
ATPases family [30,31]. Histidine and cysteine are most likely 
not involved since there is no conserved cysteine or histidine 
in L-3-phosphoserine phosphatase (see Fig. 1). Furthermore 
the lability of the phosphoenzyme to alkali and to NH2OH 
indicates an acyl-phosphate linkage, as in phosphoaspartate 
or phosphoglutamate. The low stoichiometry of phosphoryla-
tion and the lability of the phosphoenzyme bond prevented us 
from isolating a tryptic phosphopeptide suitable for sequenc-
ing. The identity of the phosphorylated residue remains there-
fore to be determined. 
Two highly conserved motifs containing aspartate residues 
are found in L-3-phosphoserine phosphatases: DXDST and 
GDGXXD. The first one shares two residues (DXXXT) 
with the consensus phosphorylation site of ATPases of the 
Na+ /K+ ATPase family. The second motif is also found in 
the same family of ATPases, where it is highly conserved (e.g., 
residues 713 to 718 of the alpha subunit of human Na+ /K+ 
ATPase). These considerations indicate that there may be 
functional homology between phosphoserine phosphatases 
and ATPases. 
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